drugset / Trial / NCT03192943

A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced Tumors

NCT03192943

Phase 1 Completed 11 enrolled Bristol-Myers Squibb
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the safety and tolerability for the combination therapy of BMS-986205 and Nivolumab in patients with advanced tumors

Timeline

Start
2017-06-23
Primary completion
2018-12-11
Completion
2018-12-11

Drugs

EvaluationDrugModalityDoseRoute
Subject LINRODOSTAT Small molecule
Subject Nivolumab Monoclonal antibody